
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc. is positioned favorably for commercialization of its key therapy, pz-cel, with a potential pathway to sustainable profitability contingent on its market uptake in the U.S. The company has demonstrated statistically significant improvements in clinical outcomes, which could support demand and reimbursement prospects. Additionally, plans to onboard high-volume treatment centers and anticipated access to significant non-dilutive capital within the next year enhance the operational capacity for pz-cel's launch, indicating a robust foundation for future growth.
Bears say
Abeona Therapeutics reported a net loss of $0.63 per share in the third quarter of 2024, with full-year 2024 net loss estimates widening to $1.62 per share, significantly higher than the initial forecast of $0.40 per share. The company faces multiple risks, including potential FDA rejection of its resubmitted biologics license application for pz-cel and uncertainty regarding market uptake in the U.S., which could adversely affect revenue and future profitability. Additionally, the substantial non-cash loss of $15.2 million related to changes in the fair value of liabilities further exacerbates concerns regarding the company's financial stability and future capital position, contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares